Statute Details
- Title: Health Products (Exemptions) Order 2016
- Act Code: HPA2007-S536-2016
- Legislation Type: Subsidiary Legislation (SL)
- Authorising Act: Health Products Act (Cap. 122D)
- Enacting Authority: Health Sciences Authority (HSA)
- Commencement: 1 November 2016
- Current Version (as provided): Current version as at 27 Mar 2026
- Key Provisions: Section 1 (Citation and commencement); Section 2 (Definitions); Section 3 (Exemptions by product category); Section 4 (Revocation)
- Schedules: First Schedule (Therapeutic products); Second Schedule (Medical devices); Third Schedule (CTGT products)
- Notable Amendments (timeline provided): S 321/2018; S 110/2021 (effective 1 Mar 2021); S 435/2023; S 804/2023
What Is This Legislation About?
The Health Products (Exemptions) Order 2016 is a Singapore subsidiary law made under the Health Products Act. In practical terms, it creates a structured set of “exemptions” from certain regulatory requirements under the Health Products framework. These exemptions are not generic; they are carefully tied to the type of health product involved—therapeutic products, medical devices, and cell, tissue or gene therapy (CTGT) products.
For lawyers and compliance teams, the Order is best understood as a gateway instrument. It tells you when a particular category of health product may be exempted from specified obligations that would otherwise apply under the Health Products Act and its product-specific regulations. Because the exemptions are set out in schedules, the Order functions like a map: it directs readers to the precise exemption lists for each product category.
Although the extract provided does not reproduce the full schedule text, the legal architecture is clear. Section 3(1)–(3) allocates exemptions to three schedules, and the definitions in Section 2 ensure that the categories are interpreted consistently with the Health Products Act and the relevant regulations (including the Therapeutic Products Regulations 2016 and the CTGT Products Regulations 2021).
What Are the Key Provisions?
1. Citation and commencement (Section 1)
Section 1 provides the formal name of the Order and states that it comes into operation on 1 November 2016. This matters for practitioners assessing transitional issues—particularly where conduct, submissions, or approvals occurred around the effective date. If a regulatory obligation was triggered before 1 November 2016, the earlier regime may be relevant; after commencement, the exemptions in the Order (as amended over time) govern.
2. Definitions and interpretive anchors (Section 2)
Section 2 defines key terms used throughout the Order. The definitions are legally significant because they tie the Order’s categories to the Health Products Act classification scheme and to specific regulations.
- “Therapeutic product” and “medical device” are defined by reference to the Health Products Act’s First Schedule classification.
- “CTGT product” is defined as a health product categorised as a cell, tissue or gene therapy product in the First Schedule to the Act. This definition is particularly important because CTGT products are often subject to more specialised regulatory controls.
- “CTGT Products Regulations” refers to the Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (G.N. No. S 104/2021), and the extract notes that this definition was inserted or updated with effect from 1 March 2021 by S 110/2021.
- “Therapeutic Products Regulations” refers to the Health Products (Therapeutic Products) Regulations 2016 (G.N. No. S 329/2016).
From a legal drafting perspective, these definitions reduce ambiguity. For example, a party cannot argue that a product is “therapeutic” or “medical device” based on marketing language alone; the statutory categorisation in the Act’s schedule controls.
3. The exemption mechanism by product category (Section 3)
Section 3 is the core operative provision. It provides that exemptions are set out in three schedules:
- Section 3(1): exemptions relating to therapeutic products are in the First Schedule.
- Section 3(2): exemptions relating to medical devices are in the Second Schedule.
- Section 3(3): exemptions relating to CTGT products are in the Third Schedule.
Although the extract does not list the specific exemptions, the legal consequence is straightforward: if a product falls within a listed exemption, the relevant regulatory requirements that would otherwise apply under the Health Products Act and its regulations may not apply (or may apply in a modified way, depending on how the schedule is drafted). Practitioners should therefore treat the schedules as authoritative and exhaustive for exemption identification.
Section 3 also reflects the legislative evolution of the regulatory regime. The extract indicates that the CTGT-related provisions were updated with effect from 1 March 2021 (S 110/2021). This suggests that the Order was amended to incorporate CTGT exemptions once the CTGT regulatory framework matured.
4. Revocation of earlier exemption orders (Section 4)
Section 4 revokes two earlier orders:
- Health Products (Medical Devices) (Exemption) Order 2012 (G.N. No. S 170/2012); and
- Health Products (Medical Devices) (Exemption No. 2) Order 2012 (G.N. No. S 427/2012).
This revocation clause is important for legal continuity. It indicates that the 2016 Order replaced earlier medical device exemption instruments. For practitioners, this means that when assessing whether a medical device is exempt, one should generally look to the Second Schedule of the 2016 Order (and its amendments), rather than the 2012 exemption orders.
How Is This Legislation Structured?
The Order is structured in a conventional subsidiary legislation format:
- Part/Section 1: Citation and commencement.
- Section 2: Definitions that anchor product categories and cross-reference the relevant product regulations.
- Section 3: The operative “routing” provision that assigns exemptions to schedules by product type.
- Section 4: Revocation of earlier exemption orders.
- First Schedule: Exemptions relating to therapeutic products.
- Second Schedule: Exemptions relating to medical devices.
- Third Schedule: Exemptions relating to CTGT products.
From a practitioner’s standpoint, the schedules are where the substantive work lies. The sections provide the legal scaffolding; the schedules provide the exemption lists and the conditions (if any) attached to each exemption.
Who Does This Legislation Apply To?
The Order applies to persons dealing with health products in Singapore—particularly where those products fall within the statutory categories of therapeutic products, medical devices, or CTGT products. While the extract does not specify “who” in the sense of regulated persons (e.g., manufacturers, importers, sponsors, distributors), the exemption framework under the Health Products Act typically affects parties who would otherwise need to comply with regulatory requirements such as licensing, registration, authorisation, or submission obligations.
In practice, the Order is relevant to regulatory counsel advising on product classification, regulatory strategy, and compliance pathways. It is also relevant to quality/regulatory affairs teams who must determine whether a product can lawfully operate under an exemption and what documentation or conditions must be satisfied to rely on that exemption.
Why Is This Legislation Important?
This Order is important because exemptions can materially change the compliance burden and timelines for bringing health products into the Singapore market. A correct exemption determination can reduce unnecessary regulatory steps, while an incorrect reliance on an exemption can expose a company to enforcement risk, including regulatory action under the Health Products Act.
For legal practitioners, the Order’s significance lies in its categorisation discipline. Section 2 definitions ensure that product type is determined by the Health Products Act classification, not by how the product is described commercially. This reduces classification disputes but increases the need for careful legal and scientific assessment when a product’s category is not obvious.
Finally, the revocation clause in Section 4 underscores that exemption regimes evolve. Medical device exemptions previously contained in 2012 orders are now consolidated within the 2016 framework. Practitioners should therefore ensure they use the current version of the Order (as at the relevant date) and check the amendment history—particularly the CTGT-related updates effective from 1 March 2021 and later amendments in 2023.
Related Legislation
- Health Products Act (Cap. 122D)
- Health Products (Therapeutic Products) Regulations 2016 (G.N. No. S 329/2016)
- Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (G.N. No. S 104/2021)
- Health Products (Medical Devices) (Exemption) Order 2012 (G.N. No. S 170/2012) — revoked
- Health Products (Medical Devices) (Exemption No. 2) Order 2012 (G.N. No. S 427/2012) — revoked
Source Documents
This article provides an overview of the Health Products (Exemptions) Order 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.